WO2006126069A2 - A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma - Google Patents

A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma Download PDF

Info

Publication number
WO2006126069A2
WO2006126069A2 PCT/IB2006/001358 IB2006001358W WO2006126069A2 WO 2006126069 A2 WO2006126069 A2 WO 2006126069A2 IB 2006001358 W IB2006001358 W IB 2006001358W WO 2006126069 A2 WO2006126069 A2 WO 2006126069A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
nucleic acid
heavy
treatment
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/001358
Other languages
French (fr)
Other versions
WO2006126069A3 (en
Inventor
Patell Villoo Morawala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avesthagen Ltd
Original Assignee
Avestha Gengraine Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008512943A priority Critical patent/JP2009508467A/en
Application filed by Avestha Gengraine Technologies Pvt Ltd filed Critical Avestha Gengraine Technologies Pvt Ltd
Priority to US11/914,750 priority patent/US20090285795A1/en
Priority to CA002609731A priority patent/CA2609731A1/en
Priority to MX2007014673A priority patent/MX2007014673A/en
Priority to EP06744761A priority patent/EP1885757A2/en
Priority to BRPI0610203-4A priority patent/BRPI0610203A2/en
Priority to AP2007004252A priority patent/AP2007004252A0/en
Priority to AU2006250888A priority patent/AU2006250888A1/en
Publication of WO2006126069A2 publication Critical patent/WO2006126069A2/en
Publication of WO2006126069A3 publication Critical patent/WO2006126069A3/en
Priority to IL187478A priority patent/IL187478A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • the present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL).
  • the treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL.
  • the procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein.
  • DNA constructs comprising the control elements associated with the gene of interest has been disclosed.
  • the nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
  • Antibodies have been considered as a powerful tool to recognize and target almost any molecule with a high degree of specificity and affinity.
  • Monoclonal antibodies (mAbs) have been used as in vitro diagnostics hence enabling worldwide standardisation of reagents for RIA, ELISA immunocytopathology and flow cytometry.
  • Monoclonal antibodies have also been extensively used for in vivo localisation of tumour antigens and in the immunotherapy of cancer.
  • the first type referred to as chimeric antibodies, wherein the murine constant domains only are replaced by equivalent domains of human origin (Morrison et al, P.N. A. S., 1984, 81, 6851-6855; Boulianne et al, Nature, 1985, 314, 268-270; and Neuberger et al, Nature, 1985, 314, 268-270).
  • the second type is where the murine constant domains and the murine framework regions are all replaced by equivalent domains and regions of human origin.
  • This second type of antibody is referred to as a humanized or CDR-grafted antibody (Jones et al, Nature, 1986, 321, 522-525; and Riechmann et al, Nature, 1988, 332, 323-327).
  • human IgGl and rat IgG2b are currently favored isotypes.
  • IgGl and IgG3 appear to be most effective for complement and cell mediated lysis, and therefore for killing tumour cells.
  • a human antibody would of course avoid the need for "humanization", however cell lines, which secrete human antibodies, are very unstable and have generally proven unsuitable for commercial scale production.
  • the anti-CD20 antibody binds specifically to the antigen CD20 (human B lymphocyte restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre B and mature B lymphocytes.
  • the antigen is also expressed on > 90% of B cell non Hodgkin's lymphomas (NHL), but is not found on hematopoietic stem cells, pro B cells, normal plasma cells or other normal tissues.
  • CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation.
  • the anti-CD20 antibody works by recruiting the body's natural defenses to attack and kill the B cell to which it binds via the CD20 antigen.
  • the host cell killing takes place by two mechanisms: 1) the complement-dependent cytotoxicity (CDC) pathway and 2) the antibody dependent cell mediated cytotoxicity (ADCC) pathway.
  • CDC complement-dependent cytotoxicity
  • ADCC antibody dependent cell mediated cytotoxicity
  • the anti-CD20 antibody is a genetically engineered chimeric murine/human monoclonal antibody.
  • the antibody is an IgG] kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences.
  • the anti- CD20 antibody is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids (based on cDNA analysis) and has an approximate molecular weight of 145 kD.
  • the anti-CD20 antibody has a binding affinity for the CD20 antigen of approximately 8.0 nM.
  • the chimeric anti-CD20 antibody is produced by mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium containing the antibiotic gentamicin.
  • the anti-CD20 antibody is purified by affinity and ion exchange chromatography.
  • the present invention relates to the construction, cloning, expression, purification and production of antibodies that can bind to CD20.
  • the antibody will be a targeted therapy indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL).
  • the present invention is directed to the transformation of nucleic acid sequence encoding the polypeptide anti-CD20.
  • nucleic acid sequences encoding the heavy and the light chains of the anti-CD 20 molecule.
  • corresponding amino-acid sequence encoded by the nucleic acid sequences.
  • a particular aspect of the invention relates to the de novo synthesis of the variable regions of the heavy and the light chain of the anti-CD 20 molecule. Further disclosed is the construction of the vector constructs with the nucleic acid sequence of interest, transformation of the vector constructs into competent bacteria and subcloning of the anti-CD 20 chains into mammalian expression vectors.
  • the anti-CD20 antibody is a mouse-human chimeric antibody. It is comprised of two chains - 1) the light chain which is made up of the variable domain derived form the light chain of the mouse monoclonal antibody 2B8 and the human kappa constant domain and 2) the heavy chain which is made of the variable domain of the heavy chain of the mouse monoclonal antibody 2B8 and the human IgGl constant domain.
  • the antibody sequence is delineated in the patent WO 94/11026.
  • the nucleotide sequence encoding the light chain of the anti-CD20 antibody has been represented in SEQ ID 1.
  • the Codon-optimized version of the nucleotide sequence encoding the light chain of the anti-CD20 antibody has been represented in SEQ ID 2.
  • the Nucleotide sequence encoding the heavy chain of the anti-CD20 antibody has been represented in SEQ ID 3.
  • Codon-optimized version of the nucleotide sequence encoding the heavy chain of the anti-CD20 antibody has been depicted in SEQ ID 4.
  • codons in the coding DNA sequence of the heavy chain of the anti-CD20 antibody that have been altered as part of the codon-optimization process to ensure optimal recombinant protein expression in mammalian cell lines such as CHO Kl and HEK 293.
  • the design of the mammalian expression vector for the expression of the anti-CD20 antibody can be based on one of the commercially available vectors (eg: pcDNA oxpIRES from Invitrogen or BD Biosciences respectively), modified to include the following features:
  • the design of the expression vector can also accommodate an independent (bi- cistronic) IRES-mediated co-expression of the green fluorescent protein which would allow rapid screening of highly expressing transfectants using fluorescence assisted cell sorting.
  • RTX-HC de novo synthesized anti-CD20 antibody-heavy chain
  • RTX-LC anti-CD20 antibody-light chain
  • the DNA was transformed into DHlOb E. coli cells and plated onto LB agar plates containing ampicillin. A colony from the plate was inoculated in liquid medium and a DNA mini prep was carried out. The sequence of the two antibody chains was confirmed by sequencing.
  • the full-length anti-CD20 antibody light and heavy chains were cloned sub-cloned into mammalian expression vectors pCAIN and pCAID respectively.
  • the pBSKII/ RTX-LC clone and the pCAIN vector were digested with BgIII and EcoRI.
  • the resultant construct referred to as pCAIN/RTX-LC.
  • the insert (700 bp) from the former and the vector backbone from the latter were gel purified and ligated (Fig. 5).
  • the ligation mix was transformed into heat shock competent DHlOb cells and plated onto LB agar plates containing ampicillin as the selection antibiotic. A few transformants were picked and a DNA mini prep was carried out.
  • the clones were checked by restriction enzyme digestion (Fig. 6).
  • the pBSKII/ RTX-HC clone and the pCAID vector were digested with BamHI and EcoRI and resultant construct referred as pCAID/RTX-HC.
  • the insert (1429 bp) from the former and the vector backbone from the latter were gel purified and ligated (Fig. 7).
  • the ligation mix was transformed into heat shock competent DHlOb cells and plated onto LB agar plates containing ampicillin as the selection antibiotic. A few transformants were picked and a DNA mini prep was carried out.
  • the clones were checked by restriction enzyme digestion (Fig. 8).
  • the cDNA construct encoding the chimeric light and heavy chain of the anti-CD20 antibody will be maintained and propagated in a standard bacterial cell line such as Top 10 (Invitrogen).
  • Transient / stable expression of the construct will be done using the Chinese hamster ovary cells (CHO) a mammalian cell line that is FDA approved for industrial applications. Transient expression is useful to check the expression of a construct and to rapidly obtain small quantities of a recombinant protein.
  • CHO Chinese hamster ovary cells
  • the mature chimeric antibody the anti-CD20 antibody is comprised of two antibody heavy chains (451 x 2 amino acids) and two antibody light chains (213 x 2 amino acids) and has an approximate molecular weight of 145 kDa. Both the chains have an N- terminal 20 amino acid leader sequence is cleaved off prior to the secretion of the hormone.
  • the current invention envisages the following steps in the purification process:
  • the percent recovery of the total protein at each stage will be quantitated using bicinchoninic acid procedure (BCA) / Bradford dye binding method.
  • BCA bicinchoninic acid procedure
  • the target protein concentration at each stage of purification will be probed using highly specific and reliable enzyme based immunoassays such as direct or indirect sandwich ELISA Qualitative and target specific western analysis will be followed at each stage.
  • Reversed phase chromatography, isoelectric focusing and two-dimensional gel electrophoresis will be employed to evaluate the purified product. Secondary structural analysis would be examined using far UV circular dichroism. Molecular mass and oligomeric status will be investigated using size exclusion and MALDI-TOF.
  • the investigations will also focus on the stability of the protein in relation to pH and temperature. As NESP is a hyperglycosylated protein, glycosylation patterns of the purified protein would be documented using gas chromatography (GC) analysis.
  • GC gas chromatography
  • Bioassays for detecting in vitro CD20 binding of the anti-CD20 antibody and the effector function of the antibody will be done using: a) Human CIq binding and CD-20 positive SB cells in a flow cytometry assay using fluoroscin labelled CIq b) Complement dependent cell lysis of CD20 positive SB cells c) Antibody dependent cellular cytotoxicity effector assay using CD20 positive cells and CD20 negative cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.

Description

A method for the production of a monoclonal antibody to CD20 for the treatment of
B-cell lymphoma.
FIELD OF THE INVENTION:
The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
BACKGROUND OF THE INVENTION:
Antibodies have been considered as a powerful tool to recognize and target almost any molecule with a high degree of specificity and affinity. Monoclonal antibodies (mAbs) have been used as in vitro diagnostics hence enabling worldwide standardisation of reagents for RIA, ELISA immunocytopathology and flow cytometry. Monoclonal antibodies have also been extensively used for in vivo localisation of tumour antigens and in the immunotherapy of cancer.
This problem has been addressed by the development of antibodies of two basic types. The first type, referred to as chimeric antibodies, wherein the murine constant domains only are replaced by equivalent domains of human origin (Morrison et al, P.N. A. S., 1984, 81, 6851-6855; Boulianne et al, Nature, 1985, 314, 268-270; and Neuberger et al, Nature, 1985, 314, 268-270). The second type is where the murine constant domains and the murine framework regions are all replaced by equivalent domains and regions of human origin. This second type of antibody is referred to as a humanized or CDR-grafted antibody (Jones et al, Nature, 1986, 321, 522-525; and Riechmann et al, Nature, 1988, 332, 323-327). For example, for therapeutic purposes, human IgGl and rat IgG2b are currently favored isotypes. Further, of the human IgG isotypes,IgGl and IgG3 appear to be most effective for complement and cell mediated lysis, and therefore for killing tumour cells. A human antibody would of course avoid the need for "humanization", however cell lines, which secrete human antibodies, are very unstable and have generally proven unsuitable for commercial scale production.
To generate sufficient quantities of antibody for full clinical use it is desirable to employ an efficient recombinant expression system. Since myeloma cells represent a natural host specialized for antibody production and secretion, cell lines derived from these have been used for the expression of recombinant antibodies. Often, complex vector design, based around immunoglobulin gene regulatory elements, is required, and final expression levels have been reported which are highly variable (Winter et al, Nature, 1988, 332, 323-327; Weidle et al, Gene, 1987, 60, 205-216; Nakatani et al, Bio/Technology, 1989, 7, 805-810; and Gillies et al, Bio/Technology, 1989, 7, 799-804). An alternative mammalian expression system is that offered by the use of Chinese hamster ovary (CHO) cells. The use of these cells has enabled the production of large quantities of several therapeutic proteins for research and clinical use (Kaufman et al, Mol.Cell.Biol, 1985, 5, 1750-1759; and Zettlmeissl et al, Bio/Technology, 1987, 5, 720-725). There are, however, very few instances of the use of these cells for the expression of antibodies and the levels of expression of murine antibodies reported to date are low of the order of 0.01-0.1. mu.g/ml (Weidle et al, Gene, 1987, 51, 21-29; and Feys et al, IntJ.Cancer, 1988, 2, 26-27).
The anti-CD20 antibody binds specifically to the antigen CD20 (human B lymphocyte restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD located on pre B and mature B lymphocytes. The antigen is also expressed on > 90% of B cell non Hodgkin's lymphomas (NHL), but is not found on hematopoietic stem cells, pro B cells, normal plasma cells or other normal tissues. CD20 regulates an early step(s) in the activation process for cell cycle initiation and differentiation, and possibly functions as a calcium ion channel. CD20 is not shed from the cell surface and does not internalize upon antibody binding. Free CD20 antigen is not found in the circulation. The anti-CD20 antibody works by recruiting the body's natural defenses to attack and kill the B cell to which it binds via the CD20 antigen. The host cell killing takes place by two mechanisms: 1) the complement-dependent cytotoxicity (CDC) pathway and 2) the antibody dependent cell mediated cytotoxicity (ADCC) pathway.
The anti-CD20 antibody is a genetically engineered chimeric murine/human monoclonal antibody. The antibody is an IgG] kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. The anti- CD20 antibody is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids (based on cDNA analysis) and has an approximate molecular weight of 145 kD. The anti-CD20 antibody has a binding affinity for the CD20 antigen of approximately 8.0 nM. The chimeric anti-CD20 antibody is produced by mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium containing the antibiotic gentamicin. The anti-CD20 antibody is purified by affinity and ion exchange chromatography.
The present invention relates to the construction, cloning, expression, purification and production of antibodies that can bind to CD20. The antibody will be a targeted therapy indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL).
SUMMARY OF THE INVENTION:
The present invention is directed to the transformation of nucleic acid sequence encoding the polypeptide anti-CD20.
According to an aspect of the invention there is provided the nucleic acid sequences encoding the heavy and the light chains of the anti-CD 20 molecule. According to an further aspect of the invention there is provided the corresponding amino-acid sequence encoded by the nucleic acid sequences.
A particular aspect of the invention relates to the de novo synthesis of the variable regions of the heavy and the light chain of the anti-CD 20 molecule. Further disclosed is the construction of the vector constructs with the nucleic acid sequence of interest, transformation of the vector constructs into competent bacteria and subcloning of the anti-CD 20 chains into mammalian expression vectors.
DETAILED DESCRIPTION OF THE INVENTION:
The anti-CD20 antibody is a mouse-human chimeric antibody. It is comprised of two chains - 1) the light chain which is made up of the variable domain derived form the light chain of the mouse monoclonal antibody 2B8 and the human kappa constant domain and 2) the heavy chain which is made of the variable domain of the heavy chain of the mouse monoclonal antibody 2B8 and the human IgGl constant domain. The antibody sequence is delineated in the patent WO 94/11026.
A de novo approach has been followed in terms of synthesis of the coding regions of cDNA-construct because the hybridoma 2B8 that secretes the anti-CD20 mouse monoclonal antibody is not available in the public domain. De novo gene synthesis would also enable codon optimization with respect to the particular mammalian cell line to be used for protein expression.
The nucleotide sequence encoding the light chain of the anti-CD20 antibody has been represented in SEQ ID 1.
The Codon-optimized version of the nucleotide sequence encoding the light chain of the anti-CD20 antibody has been represented in SEQ ID 2. The codons in the coding DNA sequence of the light chain of the anti-CD20 antibody that have been altered as part of the codon-optimization process to ensure optimal recombinant protein expression in mammalian cell lines such as CHO Kl and HEK 293. The Nucleotide sequence encoding the heavy chain of the anti-CD20 antibody has been represented in SEQ ID 3.
The Codon-optimized version of the nucleotide sequence encoding the heavy chain of the anti-CD20 antibody has been depicted in SEQ ID 4.
The codons in the coding DNA sequence of the heavy chain of the anti-CD20 antibody that have been altered as part of the codon-optimization process to ensure optimal recombinant protein expression in mammalian cell lines such as CHO Kl and HEK 293.
Choice of the Expression Vector:
The design of the mammalian expression vector for the expression of the anti-CD20 antibody can be based on one of the commercially available vectors (eg: pcDNA oxpIRES from Invitrogen or BD Biosciences respectively), modified to include the following features:
(a) A multiple cloning site for insertion of cDNA encoding both the light and the heavy antibody chains of the anti-CD20 antibody in separate expression cassettes in the same vector.
(b) The design of the expression vector can also accommodate an independent (bi- cistronic) IRES-mediated co-expression of the green fluorescent protein which would allow rapid screening of highly expressing transfectants using fluorescence assisted cell sorting.
(c) Cloning of the chimeric light and heavy antibody chains in two separate mammalian expression systems having different selectable markers. Sub-cloning of the RTX antibody chains in mammalian expression vectors
The de novo synthesized anti-CD20 antibody-heavy chain (RTX-HC) and anti-CD20 antibody-light chain (RTX-LC) were obtained as cDNA fragments cloned into the pBSKII vector and construct referred as pBSKII-RTX-LC and pBSKII-RTX-HC respectively. The DNA was transformed into DHlOb E. coli cells and plated onto LB agar plates containing ampicillin. A colony from the plate was inoculated in liquid medium and a DNA mini prep was carried out. The sequence of the two antibody chains was confirmed by sequencing.
The full-length anti-CD20 antibody light and heavy chains were cloned sub-cloned into mammalian expression vectors pCAIN and pCAID respectively. The pBSKII/ RTX-LC clone and the pCAIN vector were digested with BgIII and EcoRI. The resultant construct referred to as pCAIN/RTX-LC. The insert (700 bp) from the former and the vector backbone from the latter were gel purified and ligated (Fig. 5). The ligation mix was transformed into heat shock competent DHlOb cells and plated onto LB agar plates containing ampicillin as the selection antibiotic. A few transformants were picked and a DNA mini prep was carried out. The clones were checked by restriction enzyme digestion (Fig. 6).
The pBSKII/ RTX-HC clone and the pCAID vector were digested with BamHI and EcoRI and resultant construct referred as pCAID/RTX-HC. The insert (1429 bp) from the former and the vector backbone from the latter were gel purified and ligated (Fig. 7). The ligation mix was transformed into heat shock competent DHlOb cells and plated onto LB agar plates containing ampicillin as the selection antibiotic. A few transformants were picked and a DNA mini prep was carried out. The clones were checked by restriction enzyme digestion (Fig. 8).
DNA sequencing and analysis: The final clones of RTX-HC and RTX-LC cloned into pCAID and pCAIN mammalian expression vectors respectively were sequenced and their sequence accuracy confirmed.
Maintenance and propagation of the genes encoding the anti-CD20 antibody antibody chains:
The cDNA construct encoding the chimeric light and heavy chain of the anti-CD20 antibody will be maintained and propagated in a standard bacterial cell line such as Top 10 (Invitrogen).
Transient / stable recombinant protein expression in CHO-Kl:
(a) Transient / stable expression of the construct will be done using the Chinese hamster ovary cells (CHO) a mammalian cell line that is FDA approved for industrial applications. Transient expression is useful to check the expression of a construct and to rapidly obtain small quantities of a recombinant protein.
(b) Subsequently, CHO cells that display a stable and high expression of the desired monoclonal antibody will be developed using standard procedures.
Purification of the anti-CD20 antibody:
The mature chimeric antibody the anti-CD20 antibody is comprised of two antibody heavy chains (451 x 2 amino acids) and two antibody light chains (213 x 2 amino acids) and has an approximate molecular weight of 145 kDa. Both the chains have an N- terminal 20 amino acid leader sequence is cleaved off prior to the secretion of the hormone.
Subsequent to the establishment of reproducible bioactivity in accordance with the recommended functional / binding assays mentioned above, efforts will be made to optimize the purification procedures. The purification strategies will aim at process economics, speed to market, scalability, reproducibility, and maximum purity of the product with functional stability and structural integrity as the major objectives. To this effect, a combinatorial approach with both filtration (normal and tangential flow filtration) and chromatography would be explored. The process qualification requirements and acceptance criteria studies will be conducted on 3 batches.
Accordingly, the current invention envisages the following steps in the purification process:
a. Initial clarification using COHC / AlHC / 0.45 μ depth filters b. Concentration using Pellicon XL Biomax 50 kDa cut-off filter based on tangential flow filtration c. Chromo step - I: Affinity chromatography using Prosep VA Ultra for serum based (2 % fetal calf serum [FCS]) / and Prosep VA for serum free culture supernatants. d. Chromo step - II: Strong cation exchanger such as SP Sepharose e. Chromo step — III: Flow through based strong anion exchanger such as Cellufine Q (a cellulose based medium) for the removal of host cell proteins and nucleic acids. f. Virus removal using size exclusion filtration and leached protein A using Cellufine sulfate g. Sterile filltration h. Endotoxin removal using either Remtox / Cellufine ET chromatography h. Formulation
Establishment of the identity of the target protein using biochemical, immunological and physico-chemical methods:
The percent recovery of the total protein at each stage will be quantitated using bicinchoninic acid procedure (BCA) / Bradford dye binding method. The target protein concentration at each stage of purification will be probed using highly specific and reliable enzyme based immunoassays such as direct or indirect sandwich ELISA Qualitative and target specific western analysis will be followed at each stage. Reversed phase chromatography, isoelectric focusing and two-dimensional gel electrophoresis will be employed to evaluate the purified product. Secondary structural analysis would be examined using far UV circular dichroism. Molecular mass and oligomeric status will be investigated using size exclusion and MALDI-TOF. The investigations will also focus on the stability of the protein in relation to pH and temperature. As NESP is a hyperglycosylated protein, glycosylation patterns of the purified protein would be documented using gas chromatography (GC) analysis.
7. Assays for in vitro and in vivo activity of the anti-CD20 antibody:
Bioassays for detecting in vitro CD20 binding of the anti-CD20 antibody and the effector function of the antibody will be done using: a) Human CIq binding and CD-20 positive SB cells in a flow cytometry assay using fluoroscin labelled CIq b) Complement dependent cell lysis of CD20 positive SB cells c) Antibody dependent cellular cytotoxicity effector assay using CD20 positive cells and CD20 negative cells
Pre-clinical in vivo bioactivity of the anti-CD20 antibody will be tested on non-human primates (cynomolgus monkeys) for: a) efficacy of B cell depletion from peripheral blood lymph nodes and bone marrow. b) evaluation of any toxicity associated with the chimeric antibody

Claims

We Claim:
1. The process of preparing in vivo biologically active anti- CD 20 monoclonal antibody comprising the steps:
■ A step of De novo synthesis of the light and the heavy chains of the anti- CD20 monoclonal antibody
■ A step of construction of the full-length kappa light chain of the anti-CD 20 antibody
■ A step of construction of the full length IgGl heavy chain of the anti-CD 20 antibody
■ A step of construction of vectors comprising the nucleic acid sequences encoding the light and the heavy polypeptide chains of the anti-CD 20 molecule.
■ A step of subcloning of the anti-CD 20 antibody chains in mammalian expression vectors for production of the biologically active antibody molecule.
2. A method according to claim 1, wherein the nucleotide sequence encoding the light chain of the anti-CD20 antibody has been represented in SEQ ID 1.
3. A method according to claim 1, wherein the nucleotide sequence encoding the heavy chain of the anti-CD 20 antibody has been represented in SEQ ID 2.
4. A method according to claim 1, wherein the vector comprising the nucleic acid fragment encoding the heavy chain of the anti-CD20 is subjected to site-directed mutagenesis.
5. A method according to claim 1, wherein the full-length anti-CD20 heavy and light chain have been subcloned into mammalian vectors
6. A method of preparation of an in vivo biologically active anti-CD20 monoclonal antibody comprising steps of transforming a host cell with a vector construct of FIG No. and isolating said product from said host cell or the medium of its growth.
7. A pharmaceutical composition comprising a therapeutically effective amount of anti-CD20 antibody and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein said antibody is purified from mammalian cells grown in culture
PCT/IB2006/001358 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma Ceased WO2006126069A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2006250888A AU2006250888A1 (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to CD20 for the treatment of B-cell lymphoma
US11/914,750 US20090285795A1 (en) 2005-05-24 2006-05-24 Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma
CA002609731A CA2609731A1 (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
MX2007014673A MX2007014673A (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma.
EP06744761A EP1885757A2 (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma
JP2008512943A JP2009508467A (en) 2005-05-24 2006-05-24 Methods for generating monoclonal antibodies against CD20 for the treatment of B-cell lymphoma
AP2007004252A AP2007004252A0 (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of B-cell lymphoma
BRPI0610203-4A BRPI0610203A2 (en) 2005-05-24 2006-05-24 in vivo preparation process of biologically active anti-cd 20 monoclonal antibody and pharmaceutical composition
IL187478A IL187478A0 (en) 2005-05-24 2007-11-19 A method for the production of monoclonal antibody to cd20 for the treatment of b-cell lymphoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN624/CHE/2005 2005-05-24
IN624CH2005 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006126069A2 true WO2006126069A2 (en) 2006-11-30
WO2006126069A3 WO2006126069A3 (en) 2007-10-04

Family

ID=37452411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001358 Ceased WO2006126069A2 (en) 2005-05-24 2006-05-24 A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma

Country Status (14)

Country Link
US (1) US20090285795A1 (en)
EP (1) EP1885757A2 (en)
JP (1) JP2009508467A (en)
KR (1) KR20080039844A (en)
CN (1) CN101273063A (en)
AP (1) AP2007004252A0 (en)
AU (1) AU2006250888A1 (en)
BR (1) BRPI0610203A2 (en)
CA (1) CA2609731A1 (en)
IL (1) IL187478A0 (en)
MX (1) MX2007014673A (en)
RU (1) RU2007147598A (en)
WO (1) WO2006126069A2 (en)
ZA (1) ZA200711010B (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167540A1 (en) 2007-06-29 2010-03-31 F. Hoffmann-La Roche Ag Heavy chain mutant leading to improved immunoglobulin production
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP2010526767A (en) * 2007-03-30 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー Composition of labeled or unlabeled monoclonal antibody
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
CN103897059A (en) * 2014-03-27 2014-07-02 中国人民解放军军事医学科学院生物工程研究所 Antibody L5H7 of anit-CD20 antigen and application of antibody L5H7
CN103936856A (en) * 2014-03-27 2014-07-23 中国人民解放军军事医学科学院生物工程研究所 Antibody L4H7 with CD20-resistant antigen and application thereof
CN103936857A (en) * 2014-03-27 2014-07-23 中国人民解放军军事医学科学院生物工程研究所 Anti-CD20 Antigen Antibody L5H5 and Its Application
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP3095463A2 (en) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Methods for treating progressive multiple sclerosis
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103037900B (en) 2010-02-24 2016-04-06 伊缪诺金公司 Folate receptor 1 antibody and immunoconjugate and use thereof
IL281714B2 (en) 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing efficacy of folr1 cancer therapy
HUE049693T2 (en) 2012-08-31 2020-10-28 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
KR101723786B1 (en) 2014-03-28 2017-04-06 가톨릭대학교 산학협력단 Composition for preventing or treating B-cell lymphoma comprising IL-21 expressing mesenchymal stem cells
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN108456660A (en) * 2017-02-17 2018-08-28 浙江特瑞思药业股份有限公司 Produce high expression, the strain of high stability Chinese hamster ovary celI and its construction method of Rituximab
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (en) 2019-12-13 2025-12-26 比特比德科有限责任公司 Ingestible device for delivering therapeutic agents to the gastrointestinal tract
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
BR0206985A (en) * 2001-01-29 2005-04-19 Idec Pharma Corp Modified Antibodies and Methods of Use
DE10356112A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg A pharmaceutical composition of a beta-3 adrenoceptor agonist and a progglandin metabolite

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1915394B1 (en) 2005-05-20 2021-01-27 Lonza Biologics plc. High-level expression of recombinant antibody in a mammalian host cell
US10317393B2 (en) 2007-03-23 2019-06-11 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
US9816981B2 (en) 2007-03-23 2017-11-14 Academia Sinica Alkynyl sugar analogs for labeling and visualization of glycoconjugates in cells
JP2010526767A (en) * 2007-03-30 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー Composition of labeled or unlabeled monoclonal antibody
EP2167540A1 (en) 2007-06-29 2010-03-31 F. Hoffmann-La Roche Ag Heavy chain mutant leading to improved immunoglobulin production
US8314225B2 (en) 2007-06-29 2012-11-20 Hoffman-La Roche Inc. Heavy chain mutant leading to improved immunoglobulin production
JP2010531648A (en) * 2007-06-29 2010-09-30 エフ．ホフマン−ラ ロシュ アーゲー Heavy chain variants resulting in improved immunoglobulin production
EP3351557A1 (en) * 2007-06-29 2018-07-25 F. Hoffmann-La Roche AG Heavy chain mutant leading to improved immunoglobulin production
US10274488B2 (en) 2008-07-15 2019-04-30 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
EP3747464A1 (en) 2008-09-16 2020-12-09 F. Hoffmann-La Roche AG Methods for treating progessive multiple sclerosis using an anti-cd20 antibody
EP4364800A2 (en) 2008-09-16 2024-05-08 F. Hoffmann-La Roche AG Methods for treating progressive multiple sclerosis
US9994642B2 (en) 2008-09-16 2018-06-12 Genentech, Inc. Methods for treating progressive multiple sclerosis
EP3095463A2 (en) 2008-09-16 2016-11-23 F. Hoffmann-La Roche AG Methods for treating progressive multiple sclerosis
US9683047B2 (en) 2008-09-16 2017-06-20 Genentech, Inc. Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US11267870B2 (en) 2009-12-02 2022-03-08 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US9403855B2 (en) 2010-05-10 2016-08-02 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9874562B2 (en) 2010-05-10 2018-01-23 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10214765B2 (en) 2012-08-18 2019-02-26 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US10111951B2 (en) 2013-09-06 2018-10-30 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10918714B2 (en) 2013-09-06 2021-02-16 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9759726B2 (en) 2014-03-27 2017-09-12 Academia Sinica Reactive labelling compounds and uses thereof
US10119972B2 (en) 2014-03-27 2018-11-06 Academia Sinica Reactive labelling compounds and uses thereof
CN103897059A (en) * 2014-03-27 2014-07-02 中国人民解放军军事医学科学院生物工程研究所 Antibody L5H7 of anit-CD20 antigen and application of antibody L5H7
CN103936856A (en) * 2014-03-27 2014-07-23 中国人民解放军军事医学科学院生物工程研究所 Antibody L4H7 with CD20-resistant antigen and application thereof
CN103936857A (en) * 2014-03-27 2014-07-23 中国人民解放军军事医学科学院生物工程研究所 Anti-CD20 Antigen Antibody L5H5 and Its Application
US10618973B2 (en) 2014-05-27 2020-04-14 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10023892B2 (en) 2014-05-27 2018-07-17 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11884739B2 (en) 2014-05-27 2024-01-30 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US10533034B2 (en) 2014-09-08 2020-01-14 Academia Sinica Human iNKT cell activation using glycolipids
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
US10336784B2 (en) 2016-03-08 2019-07-02 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use

Also Published As

Publication number Publication date
EP1885757A2 (en) 2008-02-13
CN101273063A (en) 2008-09-24
MX2007014673A (en) 2008-04-08
AU2006250888A1 (en) 2006-11-30
AP2007004252A0 (en) 2007-12-31
CA2609731A1 (en) 2006-11-30
IL187478A0 (en) 2008-02-09
US20090285795A1 (en) 2009-11-19
KR20080039844A (en) 2008-05-07
RU2007147598A (en) 2009-06-27
ZA200711010B (en) 2008-11-26
AU2006250888A2 (en) 2008-04-17
JP2009508467A (en) 2009-03-05
WO2006126069A3 (en) 2007-10-04
BRPI0610203A2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
US20090285795A1 (en) Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma
JP7538721B2 (en) Anti-interleukin 17a antibodies, pharmaceutical compositions, and uses thereof
CN116003598B (en) Recombinant humanized monoclonal antibody targeting human GPRC5D and application thereof
CN106977602B (en) A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CA2992509C (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
CN116897166A (en) Anti-GPRC5DxBCMAxCD3 trispecific antibodies and their uses
WO2004085474A2 (en) Method of producing an antibody to epidermal growth factor receptor
CN106632674A (en) Anti-PD-1 (programmed cell death 1) monoclonal antibody as well as pharmaceutical composition and application thereof
CN114641311A (en) anti-TNFR 2 antibodies and methods of use thereof
CN106967172A (en) The anti-bifunctional antibodies of PD 1 of anti-CTLA 4, its medical composition and its use
WO2021127200A1 (en) Ilt3-binding agents and methods of use thereof
WO2015136471A1 (en) Anti-laminin4 antibodies specific for lg1-3
US20090220520A1 (en) Recombinant method for the production of a monoclonal antibody to CD52 for the treatment of chronic lymphocytic leukemia
WO2021041678A1 (en) Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
WO2008152537A2 (en) Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof
US20060154334A1 (en) Method of producing an antibody to epidermal growth factor receptor
CN114478788A (en) Fusion protein simultaneously targeting CD3 and CD137 and preparation method and application thereof
WO2025250941A1 (en) Cμ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
WO2025209480A1 (en) Anti-il1rap antibody and use thereof
CN118894942A (en) A domain-replaced antibody and its application
EA051720B1 (en) ANTI-INTERLEUKIN-17A ANTIBODY, PHARMACEUTICAL COMPOSITION AND THEIR APPLICATION
EA046350B1 (en) ANTI-INTERLEUKIN-17A ANTIBODY, PHARMACEUTICAL COMPOSITION AND THEIR APPLICATION

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006744761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12007502578

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 11914750

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 187478

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2609731

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014673

Country of ref document: MX

Ref document number: 2008512943

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006250888

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004252

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 5581/CHENP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006250888

Country of ref document: AU

Date of ref document: 20060524

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006250888

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077029876

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007147598

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200680026978.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006744761

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0610203

Country of ref document: BR

Kind code of ref document: A2